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The proliferation and popularity of additional treatments in IVF, also known as add-ons, has 
generated widespread discussion and controversy in the UK, where concerns have addressed 
the lack of evidence to support the efficacy and safety of these treatments, their cost, and their 
connection to a wider context of privatisation of fertility treatment. Drawing on 42 interviews 
with IVF patients, this article explores the role of hope in the appeal of add-ons from the patient 
perspective. The analysis is presented in two parts: firstly, we investigate the role of hope in 
patients’ decision-making on treatment, contextualising add-ons in the broader trajectory of 
their IVF experience; secondly, we examine how patients navigate the offer of add-ons, 
focusing on the role of hope in how they rationalise their decisions on whether to include them 
in their fertility treatment. Our analysis shows how patients craft their hope to navigate the 
increasing number of available options in their quest to find the treatment(s) that will “work” 
for them. We suggest that the imperative for patients to explore all options is intensified with 
the emergence of add-ons, which produces a novel context and version of a “hope technology”. 
 
1. Introduction  
 
In the last few decades, In-Vitro Fertilization (IVF) has become widespread worldwide. 
Although IVF birth rates have increased steadily over the years, success rates remain low 
overall: according to data published by the Human Fertilisation and Embryology Authority 
(HFEA), in the UK the average birth rate per embryo transferred was 23% in 2018 (HFEA, 
2020). Low success rates in the context of a highly-privatised sector (in England in 2018 only 
35% of IVF treatments were NHS-funded) have fostered the proliferation of additional 
treatments, or “add-ons” as they are popularly defined in the public debate, that aim to increase 
the chances of success. Although these treatments have been heavily criticised for lacking 
robust evidence of their efficacy (Heneghan et al., 2016), they are widely available and in recent 
years, over 70% of UK patients have included add-ons in their fertility treatment (HFEA, 
2019a).  
In the UK, this controversy has received extended media coverage, including a BBC 
Panorama documentary (Inside Britain’s Fertility Business, 2016) and regular articles in 








instance, Tompkins, 2019). This debate has had three focus points: the spread of add-ons as an 
effect of IVF privatisation, their costs, and the lack of evidence supporting them. These 
concerns have been echoed by the scientific literature. Scholars suggest that the 
commercialisation of add-ons is part of a wider speculative turn in IVF, with the sector 
attracting an increasing amount of venture capital and private equity investment (Van de Wiel, 
2019; 2020). Studies reviewing how add-ons are offered by British IVF clinics (Spencer et al, 
2016; Van de Wiel, et al. 2020) criticise the lack of clarity regarding their safety and 
effectiveness. For these reasons, some IVF professionals are critical toward the uncontrolled 
spread of add-ons (Rutherford, 2017; Repping, 2019) and advocate caution in offering 
potentially non-beneficial add-ons to vulnerable patients without solid evidence (Harper et al., 
2017).  
Although the debate has focused on commercialisation and the additional costs charged 
by private clinics without solid evidence to justify the use of add-ons, some add-ons are widely 
used in both public and private clinics. Some private clinics do not charge for add-ons that are 
included in their standard packages. NHS clinics also often include some of the most 
established add-ons in their all-inclusive treatment (Perrotta and Geampana, 2020), which can 
be either publicly or privately funded at costs that are similar to basic packages offered by some 
private clinics. The inclusion of add-ons in these cases is considered less controversial as 
patients are not charged extra for them, yet considering the lack of public funding in this sector, 
some consider it unethical for the NHS to invest in unproven treatments.  
The potential profiteering from unproven add-ons has been framed in the media 
coverage as “Selling Hope” (Wilkinson, 2019), pushing vulnerable couples to attempt, and 
often request, any available additional treatment in order to increase their chances of having a 
baby. The role of hope has been analysed extensively in influential works on IVF in the social 
sciences (Franklin, 1997; Becker, 2000), which express concerns about the unique IVF appeal 
of offering hope for a biological child to people who could not cultivate hope otherwise. 
Despite the, often heated, debate on add-ons, the extended literature on IVF has overlooked 
how couples make decisions regarding the inclusion of add-ons in their fertility treatments. 
Drawing on 42 interviews with IVF patients, this article fills this gap, examining the role of 
hope in add-ons’ demand. Focusing on an analysis of patients’ perspectives, this article does 
not aim to investigate what Debora Spar (2006) defines “the baby business”. However, Spar’s 
argument is relevant to contextualise our findings, as it shows how in many contemporary 
reproductive global markets (such as IVF, eggs/sperm, and surrogacy) the product on offer is 









2. The paradoxes of hope in medicine  
 
Being, in general, positively connoted within medicine, hope is considered central to 
developing strategies that can promote health (Little and Sayers, 2004; Eliott and Olver, 2007). 
In medical sociology and anthropology, hope has often been conceptualised as a resource that 
can help individuals persist through obstacles and (re)act in the face of hardship, as for instance 
with chronic illness (Mattingly, 2010). However, the paradoxical nature of hope (Mattingly, 
2010; Alaszewski and Wilkinson, 2015; Brown et al., 2015) has also been underlined. For 
instance, Mattingly argues that hope “involves the practice of creating, or trying to create, lives 
worth living even in the midst of suffering, even with no happy ending in sight” (2010, p. 6). 
Hope is required to act against and adapt to current circumstances, but cultivating hope can 
involve the risk of anticipating unrealistic futures that make patients more vulnerable to 
despair.  
In recent years, the risks of hope have been increasingly recognised in the social science 
literature on health and medicine. Scholars have argued that hope can be excessive (Brown, 
2003), unrealistic (Nabi and Prestin, 2016), or even false (Rettig et al., 2007) and that it has the 
power to propel unproven treatments that have no benefit or are even harmful for patients 
(Petersen et al., 2014). The downsides of hope have been explored in articulations of “the 
political economy of hope” (Del Vecchio Good et al., 1990; Novas, 2006; Petersen, 2015), 
which aim to underline how individual and personal endeavours are framed in a collective 
understanding of hope for a better future, which is based on biomedical promise. The desire of 
patients to participate in clinical trials or unproven and expensive treatments is fostered by 
biopharmaceutical companies and healthcare systems that have financial interests in selling 
their products. In Western biomedicine, narratives of hope are dominant (Lupton, 2003) and 
part and parcel of the great promise of science and technological innovations (Mulkay, 1993; 
Brown and Michael, 2003). On the one hand, hope has been used by bio-industries to mobilise 
resources and legitimise new forms of clinical intervention (Brown, 2005). On the other, the 
increasing availability of novel treatments and therapies offers new options and raises patients’ 
expectations in terms of possible available futures (Ezzy, 2000; Kaufman, 2015). Although we 
recognise that this dynamic of hope is shaped by the social context in which hope is enacted, 
this article focusses on what Brown and colleagues (2015) term the “lived experiences of 
hoping”, to stress the role of hope in sustaining patients’ perseverance against uncertainty and 








technologies shows that hope narratives have implications for patients, as they shape not only 
patients experience but also their actions (Herbrand and Dimond, 2018). Thus, the aim of this 
article is to explore how hope narratives influence patient decision-making on whether to 
include add-ons in their fertility treatment.  
 
3. IVF as a hope technology 
 
In a pioneering study exploring the experience of the first generation of IVF users in the UK, 
Franklin defines IVF as a “hope technology” (1997) to stress that IVF is able to offer hope to 
people who struggle with infertility “as much if not even more than a ‘successful’ outcome, 
which leads it to be seen as a desirable option, even when it is expected to fail” (1997, p. 310). 
Although the IVF success rate is statistically low (and was even lower at the time of Franklin’s 
research), it remains significantly higher than not intervening – as often patients approach IVF 
after years of involuntarily childlessness. Similarly, earlier Danish research (Koch, 1990) had 
shown how the traditional feminist critique on IVF, based on its risks and its dubious capacity 
to produce a child, was not shared by infertile women, who were following a different 
rationality based on a desire for a biological child. Franklin (1997) reinforces this argument 
showing how IVF patients are often motivated by the desire for a reproductive resolution (i.e., 
to find resolution in having tried and to accept their inability to have biological children), 
regardless of the actual outcome of treatments.  
In her work on American couples undergoing IVF treatments, Becker (2000) notes that 
patients are unable to consider alternatives to a biological child (such as adoption or living 
childless) until they have exhausted all their medical and financial resources. Becker’s 
interviewees present their IVF experience as having simultaneously too many options (in terms 
of treatment) and no other options (outside of IVF). Both Franklin (1997) and Becker (2000) 
claim that patients’ persistence against failures and their desire to “try anything possible” is 
often a tool to prevent future regret and obtain a reproductive closure. Becker (2000) suggests 
that patients’ need “to do something” about their infertility reflects American notions of 
individualism and responsibility for health, while the cultural imperative to use available 
technology against adversity pushes individuals to accept and embrace the experimental nature 
of IVF. Similarly, Franklin (1997) argues that IVF patients “living in hope” for a baby represent 
a more general Western belief in scientific progress and technological embodiment. Both 
scholars discuss the twofold nature of hope: it is necessary to “keep going” through IVF to see 








(2000) underlines that patients need to temper hope against the limitless nature of IVF, in which 
each new cycle offers new chances of a pregnancy at high emotional and financial costs. 
Franklin argues that the flipside of hope is that it can be disabling, when medical assistance 
becomes a dependency: “coming close to pregnancy, or achieving a ‘chemical pregnancy’, or 
even simply viewing her own ‘fertility’ through scans, can make it harder for a woman to accept 
her infertility than it might have been beforehand” (1997, p. 292). 
A more recent social science literature has investigated non-medical egg freezing as a 
technology invested with a particularly future oriented hope for a genetically related child. 
Unlike the hope narratives of IVF patients, where hope is focused on the more immediate 
treatment success (a pregnancy) or reproductive resolution, egg freezing allows women to 
preserve and prolong hope (Van de Wiel, 2015), thus “banking time” to negotiate future 
fertility (Waldby, 2010). Participants in Baldwin’s (2019) study of egg freezing described 
multiple narratives of hope including, importantly, the hope that their frozen eggs would not 
be needed.  
Drawing on the rich literature on hope presented above, in this article we analyse the 
role of hope in patients’ experience of IVF, focusing on how they decided whether to include 
any add-ons in their treatment. Despite the heated debate on add-ons, research on the 
perspective of patients is currently lacking. The aim of this article is not to take sides in the 
debate on the availability of add-ons, their costs, or the evidence supporting them. Rather, it 
aims to close a gap in the literature through an analysis of how patients navigate available add-
ons and how narratives of hope shape their decisions. 
 
4. Methodology  
 
The data presented in this article emerge from a larger study that considered professional and 
patient perspectives on technological innovations in IVF (Perrotta and Geampana, 2020). This 
paper focuses specifically on findings from interviews with 42 patient participants, including 
34 women going through IVF, seven male partners and one female partner. All our participants 
had at least one of the most common add-ons included in one of their treatments. As the current 
definition of add-on is porous and there is not a consensus as to what constitutes an add-on and 
what does not, we opted for an inclusive approach that acknowledged all the treatments our 
interviewees referred to as add-ons. To cover the complexity of treatment options and capture 
the experience of patients navigating both the public and private treatment contexts, 








22 participants were recruited by research nurses at collaborating NHS fertility clinics, all of 
which offered at least one of the add-ons under scrutiny by the HFEA (2019a) to their patients. 
These interviews took place in person at the clinics and primarily involved patients undertaking 
fertility treatment that was publicly funded, although this was not always the case and some 
patients were entirely self-funded or paying for additional tests or treatments.  
A second approach to recruitment took place between November 2019 and March 2020 
via an online survey, resulting in an additional 20 interview participants. The survey covered a 
range of topics relating to fertility treatment and included the option for respondents to leave 
their contact information in order to be contacted for further research participation. This survey 
was distributed online via our project blog and Fertility Network UK’s social media outlets, as 
well as by previous participants in closed IVF patient support groups. Using survey responses 
(n=314) enabled us to more purposefully select participants who had varied experiences of 
seeking fertility treatment, including their evaluations about add-ons specifically, both via NHS 
and privately funded avenues. 15 of these were interviewed over the phone, four were 
interviewed in their homes, and one was interviewed in a café setting.  
Interviews were semi-structured, including a broad introductory question that invited 
the participant to narrate a timeline of events relating to their fertility treatment, followed by 
questions organised broadly around treatment choices and options, including their approach to 
add-ons. Interviews varied in length, from 30 to 80 minutes, giving a total of 34 hours of 
interview recording. A short questionnaire was provided after the interview to collect basic 
personal information such as age, treatment financing and number of completed embryo 
transfers. As argued in research from other areas of prenatal healthcare (Farrell et al., 2019), 
we understand the individual undergoing IVF and their partner (where applicable) as “two 
members of a decision-making dyad” (ibid. p. 212) and we recognise that patients and partners 
may have different experiences of fertility treatment options. To explore these potential 
divergences, the research was designed to interview couples separately, although this was not 
a strict requirement for participation and one couple was interviewed together at their own 
request.  
In all cases, patients and partners were provided with an information letter, offered the 
opportunity to ask questions about the research and a week to consider participation prior to 
signing a consent form, which included consent to record the conversation. Each participant 
was given a £20 voucher after the interview. The study received ethics approval from the Health 








At the time of the interview, 16 participants were undergoing or about to start IVF 
treatment, 16 were pregnant or had pregnant partners, and 10 had one or more child(ren) from 
previous IVF. Although some of our participants had reached their final cycles, none of them 
had ended their treatment without being pregnant or having a baby. This is significant in 
contextualising our analysis of hope in this article as all our participants were still undergoing 
treatment or reflecting on their experience of IVF after they had attained the hoped-for outcome 
of a pregnancy or baby. It is also worth noting in relation to add-ons specifically, that 
approximately half of the participant group did not express any evaluation on add-ons, either 
because they did not consider them due to financial constraints or because they preferred to 
follow the advice of their consultant. In this article, we focus on the participants who made 
active choices or felt the desire to shape the direction of their treatment by evaluating, 
sometimes critically, the available add-ons in relation to their own treatment and in some cases 
actively seeking them. 
Patients were aged between 29 and 41, with a mean age of 35, and partners were aged 
between 33 and 47, with a mean age of 38. We experienced difficulty in recruiting men for 
interviews, which echoes a well-documented tendency in research on reproduction (Culley, 
Hudson and Lohan, 2013). Moreover, while the aim was not to recruit a demographically 
diverse participant group, the heterogeneity of our sample, which was largely white, middle 
class and heterosexual, constitutes a limitation of this research, yet it potentially reflects the 
significantly lower uptake of fertility treatments by individuals from black and ethnic minority 
backgrounds (HFEA, 2019b) as well as other sociocultural and structural barriers to accessing 
fertility treatment in the UK.  
Interview recordings were professionally transcribed verbatim. The transcripts were 
organised and coded in NVivo, and analysed following the basic tenets of a grounded theory 
approach (Charmaz and Belgrave, 2012). The analysis process involved a first-stage allocation 
of quotes to largely descriptive codes, followed by a second iteration of themes that attended 
to how patients articulated their experiences in relation to broader discursive references 
(Muncie, 2006), such as what constitutes possibility or regret in experiences of IVF. As 
patients’ narratives of hope emerged as central in how our participants describe taking 
decisions regarding the inclusion of add-ons in their fertility treatments, our analysis focuses 
on how hope can mobilise patient agency (Herbrand and Dimond, 2018) and how it shapes 











Our analysis is presented here in two parts. In the first section, we analyse the role of hope in 
patients’ experiences, focusing on how hope is essential for them to keep going with fertility 
treatment, while simultaneously highlighting how they positioned and considered add-ons in 
relation to the broader trajectory of their IVF experience, which included past procedures as 
well as expectations, plans and hopes for the future. The second section discusses how patients 
navigate the offer of add-ons and rationalise their decisions to include or omit these in their 
fertility treatment with specific reference to their association with the privatisation of fertility 
treatment in the UK, their cost and their lack of supporting evidence. In the following sections, 
we quote some participants at length to locate add-ons within their broader experiences of being 
an IVF patient. 
 
5.1 Contextualising add-ons in patients’ IVF trajectory  
 
As established through our review of the literature, hope is central to how fertility patients 
maintain the motivation to “keep going” and continue treatment in the context of adversity. 
Patients’ references to hope were complex, indicating how their sense of hopefulness fluctuated 
– emerging, fading and being actively crafted or curtailed – at different points in treatment. 
While the ultimate hope of fertility patients was to have a baby, their sense of hope could also 
have a more immediate focus, involving the hope of making progress through diagnostic or 
treatment milestones (Franklin, 1997). In this section, we develop an analysis of hope 
specifically in relation to a contemporary dynamics of evaluating, choosing or declining add-
ons. Participants in this study were generally highly reflective of the possibility that they were 
pursuing or paying for hope through their decisions to include treatment add-ons, where the 
appeal of add-ons was embedded in a future-oriented responsibility of having exhausted all 
available options that might improve their chances of pregnancy. Here, we focus specifically 
on how add-ons enter into a wider fertility treatment trajectory, which could include lengthy 
periods of diagnostic examinations as well as unsuccessful procedures. We argue that 
considering add-ons as part of this trajectory helps to understand how patients encounter them 
in a novel version of the IVF hope narrative, not only in terms of being additional options to a 
treatment that they already decided to pursue, but also in terms of accepting additional financial 
and emotional costs, on top of many other costs they had already accepted to incur. 
While many participants did not make active choices or feel the desire to shape the 








their consultant, others described the strongly felt imperative to evaluate or actively seek add-
on treatments. For example, one participant described how she was willing to “do anything” 
and that “it doesn’t matter if it hurts, if it takes longer, [or] if it takes more appointments”. 
Participants often used the language of hope to articulate the problematic sides of making 
decisions in IVF, explaining that hope can lead to emotionally driven decision-making. The 
“glimmer of light” referred to in the following quote represents a vision of potentiality that has 
the power to guide the choices made. This participant refers specifically to her decision to 
include intralipid infusions in her IVF, which she refers to in the following quote as “the egg 
yolk thing”, and she also highlights the informal networks of knowledge sharing about add-ons 
in IVF, including the sharing of experiences between patients: 
 
Before we were put into our treatment plan, I had another friend who had had 
unsuccessful IVF treatment but she had had this egg yolk thing. And when she told me 
about it the first thing I did was look it up and I asked about, I asked [my consultant] 
about it. So I would say that had there been other things that were available to us or, 
and it was relevant to our treatment, I probably would have [requested them]. Because 
when … Yeah, like I said it’s such an emotionally, you know, you can get into some 
very dark places and whatever offers a glimmer of light you are drawn towards, I think, 
yeah. (Patient, became pregnant from first embryo transfer and had baby, awaiting 
further IVF). 
 
Hope was often something that participants in this research actively pursued following 
bad news, such as in response to an infertility diagnosis or a negative pregnancy test result after 
embryo transfer. In these cases, “getting hope back” was coupled with renewing belief in 
treatment and feeling emotionally ready to continue. Participants often described a sense of 
pride and achievement at reaching the stage of having one or more viable embryo(s) to transfer, 
and some talked about the transfer as the closest they had ever been, or may ever be, to a 
pregnancy. Crucially, having embryos to transfer is not a given in the context of IVF and 
several participants had been through rounds of egg collection and fertilisation without having 
any viable embryos to transfer. The following participant reflected on how she had felt positive 
and hopeful at getting to the stage of embryo transfer, which, even if it did not lead to a 
pregnancy, would hopefully provide some information that would be valuable in moving 









From when it the embryo was transferred, it was like I suddenly got loads of hope. I 
just thought “oh my God, this could actually work now.” And yeah, it was a really 
strange time because I’m really negative and I was suddenly really, really positive about 
it and just couldn’t believe it and I said to my husband: until potentially we lose this 
baby I’m actually pregnant now and I’ve never been pregnant. So I thought at the very 
least, you know, at least if the baby sticks for a while then we can really get some 
answers about what’s wrong and at least then, you know, maybe it might work next 
time if there’s something else that I need. (Patient, six years of diagnostic examinations 
and reducing BMI to meet IVF criteria, pregnant from first embryo transfer). 
 
In a context where there are a vast number of potentially available fertility treatments 
or procedures, the end of the previous quote underlines the future-oriented notion that 
“something else” might offer the right treatment that would make a difference for the success 
of the procedure. In other words, the availability of add-on treatments expands the range of 
possibility and treatments to try. The following participant articulated the promise of hope that 
is attached to add-ons specifically, and she located this dynamic within a broader view of IVF 
as “a bit of a scientific experiment”. Challenging the media portrayal of fertility patients, this 
participant specified that patients, in her view, do not act in “blind faith” but are making 
decisions about add-ons in a context where there are many unknowns about the efficacy of 
treatments and, in the context of privately funded IVF, the possibility of paying for hope has 
strong appeal:  
 
The way it’s portrayed sometimes is that people, because they’re in a vulnerable state, 
they get, they get over-sold certain things because they get sort of sold a bit of a 
pipedream that if you have this extra or this extra, then that’s the thing that will make 
it work, that, and that these can sometimes add up for people. Which I think sometimes 
in the media comes from a place of not understanding what it’s like, fertility treatment, 
and the fact that you’re already paying ten grand, it doesn’t matter, you know, and 
you’ll do anything and you know, the whole thing is a bit of scientific experiment in 
that you’re just, you know, you, that you have sort of, it’s sort of not blind faith but 
your hope is such that you, if someone says something will work then you might tend 








add-on is that, isn’t it? (Patient, had one viable embryo from each egg collection, two 
embryos transferred over two years, awaiting third egg collection). 
 
 Some participants reflected on the timing of their considerations around the inclusion 
of add-ons in their IVF. In cases where the causes of infertility were not known, many patients 
described a preference for trying “standard” or “basic” IVF first before pursuing additional 
treatments. The following participant, however, described how she had chosen to undergo a 
biopsy for endometrial natural killer cell testing as well as acupuncture from the start, and she 
was having pre-implantation genetic testing (previously known as pre-implantation genetic 
screening or PGS) of the embryos created from her next egg collection. For this patient, 
including and paying for add-ons from early in the treatment process was an attempt to reduce 
the time to pregnancy and thus reduce the emotional and physical costs of IVF:     
 
We’ve probably done things earlier than most people would, so probably most people 
would get to the end of their NHS funded cycles and then go and have all of those tests 
whereas we decided to have them done earlier on. I guess we’re a bit impatient …  
We didn’t do it PGS with our first cycle because you wouldn’t, our consultant has 
said it, obviously that you learn something from every cycle and every transfer that you 
go through, to sort of tailor things and try and make it better for the next time and one 
of the things that obviously we didn’t do for our first was PGS. We had a long think 
about it and actually if we, if we go down the route of having them all checked then if 
there are, you know, or if we have six embryos generated and we have four that are 
aneuploid then that saves us four transfers, the heartbreak of four failed transfers which 
actually is, it’s more a matter of heartbreak, it’s a lot of upset so. And also, the hormones 
that I’m putting in my body, which if I don’t have to do that it’s probably better for me 
in the long run. (Patient, four embryo transfers, preparing for second egg collection). 
 
 Participants’ considerations and decisions about add-ons must be positioned as part of 
a broader experience and trajectory of IVF treatment, which potentially involves significant 
emotional, physical and financial investment over an extended temporal scale. As demonstrated 
through the previous quote in particular, add-ons are embroiled in an imperative to “tailor” 
treatment and “make it better for the next time”, which enables add-ons to always offer 









5.2 Evaluating add-ons: Privatisation, cost and evidence 
 
In this section, we focus on the three most controversial aspects of add-ons as represented in 
the public debate about IVF in the UK: the spread of add-ons as an effect of the privatisation 
of the field; their costs; and their lack of supporting evidence. Although add-ons emerged in 
the narratives of our participants as central to their pursuit of treatment success, they often 
challenged the assumption that fertility patients uncritically accept additional tests or 
treatments that are offered to them. Patients do not “blindly” accept add-ons but they are 
working within a treatment context that calls for them to consider all relevant options and weigh 
these up against overall costs of treatment, which was especially pertinent for those who had 
pursued IVF through privately-funded avenues. The following participant, who for a short 
period had considered both a private and an NHS clinic for self-funded treatment, reflected on 
the main differences they encountered between these clinics: 
 
We had a look at one private clinic before we started this process. Just basically to see 
what is it, is there something there that is different. Because it doesn’t strike us as being 
logical, why would you go to a private clinic? I understand that you have to pay here 
[NHS clinic], that’s a whole different story. But kind of thing, why would you then go 
to an outside body if the price is going to be, looking at it online the price seemed to be 
about the same so we thought we’ll go and have a look and see what is it that is different. 
We did and it wasn’t disastrous, it was reasonably clean and reasonably nice but it 
offered absolutely nothing better than here and in fact, there were quite a few things 
that were offered that were very dodgy. So we’ve done our research in terms of all the 
added extras, all the various scratches and various vitamin supplements, these kind of 
things and most of them, [according to] the HFEA [have] absolutely zero evidence that 
they provide any benefit, yet in the private clinic this was something that they were 
talking about. We’ll give you all this special yogurt and everything, all of which are, it 
would appear, clinically speaking nonsense. (Partner, three embryo transfers over one 
year, one early miscarriage, awaiting fourth egg collection). 
 
This participant shared concerns about the privatisation of the sector by describing the 
potential profiteering from unproven add-ons by rapacious private clinics and challenging the 








and “clinically speaking nonsense”. Specifically, he referred to the endometrial scratch and 
intravenously administered intralipid infusions (“special yogurt”), neither of which are 
currently supported by conclusive evidence that they improve pregnancy rates. It is also worth 
noting that various additional treatments were mentioned in this interview, including things 
like vitamins, which are not considered add-ons by the medical literature and HFEA. Although 
the term “add-on” usually refers to additional drugs, tests or lab equipment, the proliferation 
of products and services offered, from alternative medicine to the wellness industry, adds a 
further layer of complexity to patients’ navigation of treatment options. In addition, the divide 
between the NHS (publicly funded) and private fertility clinics was often unclear. In reflecting 
on their joint decision to request the endometrial scratch and embryo glue in their paid IVF 
treatment at an NHS clinic, the following partner described the “strangeness” of making 
choices about whether or not to include certain add-ons: 
 
They’re kind of strange choices to be making but then also potentially very beneficial 
to making things happen but it’s quite …  I don't know if it’s part of being in this country 
where you kind of [receive] NHS care and it is what it is, and you go and you talk 
through your choices rather than… It felt a little bit more like kind of picking additional 
add-ons that you wanted which is not something that I was used to and not as a bad 
thing but it, again that took quite a bit of getting used to, thinking about, you know, “oh, 
shall we have this as well” and… Yeah, it’s quite a strange mentality to get your head 
round [...] I think with some of the additional things it, you could just keep going and 
keep going and I think it had all got a bit, we kind of reached that point, that limit point. 
(Partner, wife had baby from first embryo transfer). 
 
The inclusion of some add-ons in NHS-funded IVF legitimises their use beyond the 
NHS, where receiving a certain treatment as an NHS patient creates expectations as well as the 
conditions to request the same treatment as a private patient, even if this is offered at an 
additional cost. The following participant portrayed a highly individualised sense of 
responsibility in her decision-making that was tied to a felt imperative to avoid future regret, 
and she described her process of rationalising add-ons in relation to the high cost of IVF as a 










If I was a private patient and I was offered [a treatment] as an add-on I would have paid 
for it if I was told it worked. I think, I think you’d pay for anything really. If you’re told 
it works and it’s £500 you’d think well, I don’t want to not spend the £500 and it didn’t 
work because of that […] I’ve never felt under pressure to pay for anything but I’m an 
NHS patient so maybe if I was sitting … See if I have a third cycle, which I hopefully 
don’t want to, but if I have a third cycle that will be as a private patient. So maybe my 
experience will be different but then, am I going to turn down the [endometrial] scratch 
when I’ve had it for all the other ones? And maybe I think well, it didn’t work, but 
maybe I think well, that was other issues that didn’t work and actually if I don’t then 
have the scratch we will have paid for all this but… I think you sometimes think that if 
you’re paying all that money you don’t want to scrimp and waste £5,000 by not paying 
for the scratch. (Female patient, five embryo transfers, awaiting further diagnostic 
examinations and treatment). 
 
Yet participants in this study demonstrated a variety of perspectives on the considerable 
cost of many add-ons. The first quote below situates costs against possible improvements to 
chances of pregnancy, however tenuous or minute, and a future-oriented imperative to exhaust 
all available options, whereas the second presents a more sceptical perspective on the need to 
invest additional financial resources to obtain a pregnancy: 
 
And then our consultant told us about available add-ons and because we are in the 
fortunate position we could pay for it we kind of, just were like yeah, yeah, yeah, we’ll 
do it all, you know, we just do whatever might help. (Female patient, became pregnant 
from second embryo transfer four years ago and had baby, entered treatment again 
since, pregnant from second frozen embryo transfer). 
 
If you’ve got the money to have all of these expensive add-ons that may or may not 
work great but we don’t so I was happy to just go straight down and get on with the 
treatment and that will be it. And like I said, if they’d offered me the scratch at an extra 
£200 I probably wouldn’t have done it because you know, people get pregnant without 
having it anyway so, no. (Female patient, three years of diagnostic examinations and 









In explaining her approach to add-ons, another participant described contrasting modes 
of rationality between what she terms her “scientific brain” and her sense of “woolly thinking”, 
where the latter was attached to an intense desire to improve her chances of having a baby 
despite knowing that some add-ons lack rigorous evidence to support their use: 
 
When I was given the option of things [such as add-ons] my scientific brain then sort 
of went out of the window and was pushed to one side. Because I was like, well, I don’t 
really care now if there’s not any good evidence for this, if it gives me a better chance 
of having a baby then we’ll do it. So I kind of have my standards and then I’m like, you 
know, I sort of threw them out of the window really. I suppose for me, I kind of have a 
feeling if some, if something will be actively bad for me if you like… then I wouldn’t 
go down that route […] [or] if it was like, an add-on or a treatment that I’d not really 
heard of being used on a wide basis or I couldn’t see any sort of rationale for it. But I 
feel that I did go rather woolly and sort of not very scientific thinking towards the end. 
Because you do, you do start to think well, let’s just throw everything at it and see if it 
works. (Female patient, had one viable embryo from each egg collection, two embryos 
transferred over two years, awaiting third egg collection). 
 
This participant expressed a desire to “throw everything at it” but also noted three 
particular reservations about add-on treatments, including whether the treatment in question 
could cause harm, whether it is widely available, and what constitutes the rationale behind its 
use. She was familiar with medical terminology around evidence base and previously in the 
interview she had cited the importance of randomised control trials in supporting new 
treatments. She also echoed many other participants who expressed a sense of being burdened 
by the responsibility of navigating the treatment options that are available to them, and it was 
particularly in relation to weighing up the options that she described the difficulty of 
maintaining a grasp on her “standards” of evaluating evidence. Throwing “everything at it” 
aligns with our previous observation that patients present the IVF experience as a quest to find 
the one treatment or combination of treatments that will “work” for them. Evaluating add-ons 
is thus connected to patients’ broader acknowledgement of the many unknowns and 
uncertainties associated with IVF, and these uncertainties are further compounded by the fact 












Both the public debate and scientific literature on the add-ons controversy in IVF focus on 
criticisms regarding the proliferation of add-ons, their high cost, and the fact that none of these 
treatments have solid evidence of their safety and efficacy at increasing pregnancy rates. As 
add-ons are very popular in the UK, these criticisms generally imply that patients are vulnerable 
and irrational in their treatment decision-making regarding add-ons. By contextualising add-
ons in patients’ IVF trajectory, our analysis offers a more nuanced understanding of how 
patients make decisions regarding the inclusion of add-ons in their fertility treatments. We use 
the term “IVF trajectory” to underline the common path, presented in the literature on IVF 
(Franklin, 1997; Becker, 2000) and confirmed by our participants, that the IVF experience 
entails. Dealing with infertility means accepting medical support, facing the emotional and 
financial hardship of IVF treatment, accepting its “experimental nature”, low success rates and 
that, therefore, multiple attempts need to be made. Our focus on what we term “the crafting of 
hope” underlines how patients’ decisions about whether to include add-ons are shaped by the 
dominant discourse of hope in IVF, while at the same time, patients have to continuously curtail 
and balance hope against other considerations, such as potential harm, emotional costs, and 
financial resources. 
Our findings confirm the dominant IVF discourse on hope illustrated by the literature, 
which considers hope as essential to persevering against adversity, and show how this discourse 
is amplified by the proliferation of add-ons, which emerge as novel versions of the “hope 
technology” (Franklin, 1997). To “keep trying” and “try everything” to avoid future regret are 
part of the dominant discourse of hope circulating among patients. Our findings show that this 
discourse is extended to add-ons, which become part of the search for the “right” treatment that 
will lead to success (a pregnancy) or to a resolution (accepting that is not possible to have a 
biological child). Similarly to what has been noticed in the case of egg freezing (Waldby, 2010; 
Van de Wiel, 2015; Baldwin, 2019), add-ons prolong hope in the sense that they foster a 
narrative according to which the “right” treatment has not yet been found. As the literature has 
shown, patients’ persistence despite failures is closely tied to a reluctance to consider 
alternatives to a biological child until they have exhausted all their medical and financial 
resources (Franklin, 1997; Becker, 2000). The proliferation of add-ons offers virtually infinite 
options to create the illusion that more things can be tried, raising patients’ expectations in 
terms of possible available futures (Ezzy, 2000; Kaufman, 2015). Our findings confirm that 








reproductive closure, and this influences how they make decisions regarding the inclusion of 
add-ons in their fertility treatments. 
Although our findings show patients’ concerns regarding the role of their emotions in 
their decision making, our participants do not accept add-ons uncritically. Mirroring the 
literature (Koch, 1990), our findings reveal that patients are not irrational in their decision-
making, but they follow a rationality that is based on a desire for a biological child and 
considers their available options. For instance, when discussing add-ons, patients are concerned 
about what they actually offer, their costs and the lack of scientific evidence. However, their 
rationality remains based on achieving the desired outcome (i.e., having a baby) as soon as 
possible. Patients acknowledge that this rationality does not conform to what is considered a 
“scientific” one, but in their experience, other issues are relevant in evaluating add-ons. Some 
participants were concerned about being offered “dodgy things” by private clinics, and they 
problematised the divide between public and private sectors as represented in the public debate. 
In terms of the additional costs of add-ons, our participants contextualised them in terms of 
their personal circumstances (whether they are in the position to afford to invest financial 
resources in the treatment or not determine their actual options) and in their IVF trajectory 
(where the cost of additional treatments is usually fractional compared to the cost of the IVF). 
Similarly, patients’ evaluations of the evidence to support the safety and efficacy of add-ons 
does not follow a “scientific” rationality, but rather evidence are evaluated on the basis of 
different criteria, such as whether an add-on is widely available. These criteria are not 
irrational, but they emerge from the narratives of hope described above, on the basis of which 




Despite the often heated debate on add-ons, the extended literature on IVF has overlooked how 
patients make decisions regarding the inclusion of add-ons in their fertility treatments. This 
article fills this gap by examining patients’ perspectives and focusing on how dominant IVF 
hope narratives shape patients’ decision-making. Attending to the role of hope is, we argue, 
central to understanding how add-ons become part of an increasingly complex medical and 
technological landscape of treatment options for IVF patients. Notably, as we did not interview 
individuals who decided to end treatment without a baby, our findings cannot offer any insights 









Our findings confirm the following key elements of the dominant IVF hope discourse 
(Franklin, 1997; Becker, 2000): the need to “try anything possible” to find reproductive 
resolution and prevent future regret; the need to accept the experimental nature of IVF; and the 
need to exhaust all available medical and financial resources before considering alternatives to 
a biologically related baby. These narratives are fuelled by the availability of so many add-ons, 
which expands the number of options to try. This can increase the risk of anticipating unrealistic 
futures (Del Vecchio Good et al., 1990; Brown, 2003, 2005; Novas, 2006; Petersen, 2015) and 
make patients more vulnerable to the allure of the IVF market. These narratives encourage the 
promise of novel (and often unproven) biomedical interventions (Petersen et al., 2014), making 
it difficult for patients to resist or refuse to consider additional treatments. Our findings 
contribute to this body of literature, showing how macro level discourses and processes of 
commercialisation in the offering of new treatments shape not only the possibilities imagined 
by patients, and therefore their expectations and experiences, but also their actual treatment 
decisions. Our findings also attend to Spar’s (2006) argument, by confirming that the 
commercialisation of add-ons requires careful regulation for protecting patients from the allure 
of the market. In other Western countries where treatment is largely funded publicly (for 
instance, in the Netherlands or France), add-ons are relatively uncommon. 
In this article, we introduce the concept of “crafting hope” to underline how IVF 
patients navigate the complex dynamics and tensions that characterise the IVF trajectory in a 
highly competitive market. Our findings show a broad concern with making emotionally-
driven treatment decisions in a stressful and uncertain context such as fertility care. We argue 
that patients crafted hope through careful consideration of whether to emotionally and 
financially invest in potentiality or curtail and temper hope to prevent potential harm. This 
dynamic of hope provided the foundation for patients to claim their agency and active role in 
treatment decisions and to refuse the notion that their vulnerability makes them uncritically 
accept any additional treatment available.  
Given that numerous add-ons are available through an unregulated market, patients 
carry the burden of decisions about what to include in their treatment in a context that promotes 
the model of the persistent patient who wants to “try anything possible” to avoid future regret. 
As our findings show, not all patients adhere to this model; however, these narratives widen 
inequalities in fertility care. While for patients who are able and willing to pay for additional 
treatments, these can sustain the hope for a biological child, for those with less financial 
resources the availability of add-ons may hinder patients’ ability to avoid regret and find 








emotional and financial burden. Therefore, we argue that the dynamics presented in this article 
should be taken into consideration as a key aspect of the ethics of care in IVF, and clinics 
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